Dialybrid raises €15 million for Silkothane graft trial
AI Summary- Dialybrid closed a €15 million Series A led by XGEN Venture, with CDP Venture Capital participating.
- €15 million will fund clinical development and preclinical Silkothane® work in other vascular applications.
- Dialybrid’s first-in-human study will enroll 18 adults across four Italian centers.